ClinicalTrials.Veeva

Menu

Full Spectrum Hemp Observational Study

C

Charlotte's Web, Inc

Status

Unknown

Conditions

Acne Vulgaris Superficial Mixed Comedonal and Inflammatory
Acne Vulgaris

Treatments

Drug: Full-spectrum hemp (0.018% THC)

Study type

Observational

Funder types

Industry

Identifiers

NCT04730414
Charlottes Web, Inc

Details and patient eligibility

About

In westernized societies, acne vulgaris is nearly a universal skin disease afflicting 79% to 95% of the adolescent population; older than 25 years - 40% to 54% have facial blemishes and persists into middle age in 12% of women and 3% of men. Standard treatment modalities present with high risk morbidities. Charlotte's Web hemp blemish product is predicted to significantly reduce the risks mentioned above, while improving efficacy as well as imparting other skin benefits.

Full description

Charlotte's Web Full spectrum hemp blemish product will contain a mere 0.018% THC and will therefor not impart a psychotic affect. Hemp has been shown to be well tolerated in humans and has a very acceptable dosage, efficacy and safety profile when topically applied. The FDA has labeled hemp as Generally Regarded As Safe (GRAS) and as such reduces the risk of severe adverse reactions to the subject.

Benefits of hemp blemish 'cream" is that it has been formulated in such a way as to promote natural skin balance, and may eliminate skin dryness, inflammation, hyperpigmentation, and scaring.

The primary objective and endpoint of the study is to obtain total eradication of the blemish eruptions. The secondary objective and endpoints is the continued use of the hemp product will continue to prevent further blemish eruptions and provide other skin benefits especially reducing the propensity to scar.

Enrollment

50 estimated patients

Sex

All

Ages

13 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male/female
  • Diagnosed acne vulgaris
  • Not on current acne treatment(s) or off current treatment for 2 weeks
  • 13-70 yrs old

Exclusion criteria

  • Not willing to stop current acne treatment(s)
  • males that present with facial hair
  • active TB, HIV or hepatitis
  • pregnant or lactating females

Trial design

50 participants in 1 patient group

Age, Male, Female, ethnicity,
Description:
The aim of the study is to be inclusive of all groups as to avoid bias. Furthermore, the study aims to determine if its formulation will encompass all skin types, genders and age groups. Full-spectrum hemp dosage is determined to begin with 40mg - 2-3X/day = topical application; for a period of 2-3 months. Drug: Full Spectrum hemp (0.018% THC), Topical Application Placebo = cream without hemp (Double blinded) One cream will be placed on one side of the face (R/L) and the other cream on the other side of the face.
Treatment:
Drug: Full-spectrum hemp (0.018% THC)

Trial contacts and locations

0

Loading...

Central trial contact

Jeff Lokken, BS, MS; Sherry Bradford, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems